• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Akebia Therapeutics Inc.

    4/30/25 10:57:38 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKBA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Akebia Therapeutics Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    00972D105

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    00972D105


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    136,460.00
    7Sole Dispositive Power

    12,470,283.00
    8Shared Dispositive Power

    215,520.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    12,685,803.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.37 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Akebia Therapeutics Inc
    (b)Address of issuer's principal executive offices:

    245 First Street, Suite 1100, Cambridge, MA, 02142
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    00972D105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    12685803
    (b)Percent of class:

    5.37  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    136460

     (iii) Sole power to dispose or to direct the disposition of:

    12470283

     (iv) Shared power to dispose or to direct the disposition of:

    215520

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:04/30/2025
    Get the next $AKBA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AKBA

    DatePrice TargetRatingAnalyst
    6/4/2025$8.00Buy
    H.C. Wainwright
    4/28/2025$7.00Outperform
    Leerink Partners
    4/1/2025$6.00Buy
    Jefferies
    11/29/2023$4.00Buy
    BTIG Research
    8/28/2023$3.75Neutral → Buy
    H.C. Wainwright
    5/31/2023$2.00 → $4.00Neutral → Overweight
    Piper Sandler
    3/31/2022$10.00 → $2.00Buy → Neutral
    H.C. Wainwright
    3/31/2022Buy → Hold
    Needham
    More analyst ratings

    $AKBA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on Akebia Therapeutics with a new price target

      H.C. Wainwright resumed coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $8.00

      6/4/25 7:33:29 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Akebia Therapeutics with a new price target

      Leerink Partners initiated coverage of Akebia Therapeutics with a rating of Outperform and set a new price target of $7.00

      4/28/25 8:36:09 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Akebia Therapeutics with a new price target

      Jefferies initiated coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $6.00

      4/1/25 9:03:14 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKBA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

      CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Nik Grund, Chief Commercial Officer, will participate in a Fireside Chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on Monday, July 14 at 10:00 AM EDT. A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com following the conference. About Akebia TherapeuticsAkebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of p

      7/8/25 8:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 141,800 shares of Akebia's common stock on June 30, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $3.64 per share, which is equal to the closing price of Akebia's common stock on the grant date. The stock options vest over four years, with 25% of th

      7/1/25 4:05:00 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

      CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Journal of the American Society of Nephrology (JASN) has published pre-specified analyses for the U.S. and non-U.S. patient subgroups from the vadadustat global phase 3 clinical program, which included two trials in patients with dialysis-dependent chronic kidney disease (DD-CKD; INNO2VATE) and two trials in patients with non–dialysis-dependent CKD (NDD-CKD; PRO2TECT). The vadadustat global phase 3 clinical trials were open-label, randomized, noninferiority trials that c

      6/4/25 8:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKBA
    SEC Filings

    See more
    • Akebia Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)

      6/13/25 7:21:17 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Akebia Therapeutics Inc.

      10-Q - Akebia Therapeutics, Inc. (0001517022) (Filer)

      5/8/25 7:29:11 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)

      5/8/25 7:04:15 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKBA
    Financials

    Live finance-specific insights

    See more
    • Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, May 8, 2025, at 8:00 a.m. EDT to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time.  A live webcast of the conference ca

      5/1/25 8:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

      Strong results to date of Vafseo U.S. launch; expect Vafseo Q1 2025 net product revenues of approximately $10-$11 million Cash resources and cash from operations expected to fund current operating plan for at least two years Akebia to Host Conference Call at 8:00 a.m. ET on March 13, 2025 CAMBRIDGE, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the fourth quarter and full year ended December 31, 2024 and recent business highlights. As previously announced, Vafseo® (vadadustat) shipments to customers began Januar

      3/13/25 7:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

      CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2024, on Thursday, March 13, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, March 13, 2024, at 8:00 a.m. ET to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time.  A live web

      3/6/25 8:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKBA
    Leadership Updates

    Live Leadership Updates

    See more
    • Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer

      CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Nicholas Grund as Chief Commercial Officer. Mr. Grund is a seasoned pharmaceutical executive with significant operational, commercial and strategic leadership experience across renal and specialty markets. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeut

      1/9/24 8:30:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Appoints Ron Frieson, Healthcare Operations Leader, to Board of Directors

      CAMBRIDGE, Mass., Nov. 1, 2021 /PRNewswire/ -- Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Ron Frieson to its Board of Directors. Frieson currently serves as the Chief Operating Officer of Children's Healthcare of Atlanta (CHOA), a non-profit corporation whose mission focuses on bettering all aspects of children's healthcare. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt

      11/1/21 8:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKBA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Akebia Therapeutics Inc. (Amendment)

      SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)

      2/13/24 4:58:48 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Akebia Therapeutics Inc. (Amendment)

      SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)

      2/9/24 4:00:47 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Akebia Therapeutics Inc. (Amendment)

      SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)

      2/10/23 1:08:17 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKBA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, CFO, CBO & Treasurer Ostrowski Erik sold $151,622 worth of shares (41,314 units at $3.67), decreasing direct ownership by 8% to 503,586 units (SEC Form 4)

      4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

      7/1/25 5:01:37 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Zumwalt Leanne M was granted 35,700 shares, increasing direct ownership by 48% to 109,400 units (SEC Form 4)

      4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

      6/11/25 5:16:36 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Adams Adrian was granted 35,700 shares, increasing direct ownership by 22% to 200,500 units (SEC Form 4)

      4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

      6/11/25 5:16:12 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKBA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for VAFSEO issued to AKEBIA THERAPEUTICS INC

      Submission status for AKEBIA THERAPEUTICS INC's drug VAFSEO (ORIG-1) with active ingredient VADADUSTAT has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 215192, Application Classification: Type 1 - New Molecular Entity

      3/28/24 10:46:38 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care